Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS

Conclusion Despite observing zero responses, a majority of patients had stable disease and eight patients had stable disease lasting longer than 5  months. These results suggest that linifanib has some anti-tumor activity inKRAS mutant metastatic and refractory CRC.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research